By Amirah Al Idrus
A month after moving its COVID-19 antibody cocktail into human trials, Regeneron is starting a phase 3 study to see whether the drug can ward off infection in people exposed to COVID-19 patients. To be conducted with the National Institute of Allergy and Infectious Diseases, the trial aims to enroll 2,000 patients through about 100 sites in the U.S.
read more
By Robert King
A new Senate bill seeks to preserve 340B eligibility for hospitals impacted by the COVID-19 pandemic.
read more
By Angus Liu
As COVID-19 vaccines near final stages of testing, governments are also racing against each other, busy securing supply for their own countries. The U.K. government, on the heels of locking up delivery from AstraZeneca, is reportedly ready for more doses from an alliance between Sanofi and GlaxoSmithKline.
read more
By Conor Hale
The FDA issued a new emergency authorization to the Centers for Disease Control and Prevention for a combination influenza and COVID-19 diagnostic test—as the U.S. prepares to enter its annual flu season later this year in the midst of a global pandemic.
read more
By Healthcare Staff
Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.
read more
By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner
J&J inked a five-year deal with Emergent to make doses of its COVID-19 vaccine. Regeneron and Sanofi axed U.S. trials of Kevzara in COVID-19 after a phase 3 flop. Moderna's shares took a hit after reports surfaced that it might delay its vaccine trial start. Plus, the CDC is rolling out a combo flu/COVID-19 diagnostic.
read more
By Ben Adams
Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report by Stat said the biotech would have to delay the start of its major phase 3 pandemic vaccine trial.
read more
By Beth Snyder Bulik
The COVID-19 pandemic placed China in the spotlight, not only because it had the first cases of the disease but because it had some of the earliest reopenings. It’s an unenviable position, but one that can give insight into the impact on the pharma industry across issues such as digital engagement, healthcare access and communications.
read more
By Heather Landi
As COVID-19 cases continue to rise in parts of the U.S., many primary care practices are not ready to address the current surge or a second wave predicted to come in the fall.
read more
By Kyle Blankenship
In the early days of the COVID-19 pandemic, Sanofi and Regeneron launched an ambitious plan to try out rheumatoid arthritis med Kevzara in desperately ill patients. But after early warning signs, a phase 3 flop has forced the drugmakers to can their U.S. trial.
read more
By Robert King
A new report sought to shed light on the spread of the novel coronavirus in assisted living facilities, which have a fatality rate comparable to nursing homes.
read more
By Beth Snyder Bulik
GlaxoSmithKline had big growth plans for 2020 across its brands—and then the COVID-19 pandemic hit. So the company scrambled to rethink and prioritize “ruthlessly” to find a new way forward. That meant leaning even harder into digital and e-commerce, as well as realigning brand categories to reflect COVID-19 consumer thinking, GSK Chief Marketing Officer Tamara Rogers told attendees of the recent virtual Cannes Lions Live conference.
read more
